Table 2.

Outcomes. CI, confidence interval; ICU, intensive care unit; IQR, inter-quartile range; SAE, serious adverse event. ∗Data regarding primary outcome were missing for one patient in the higher oxygenation group. ^†Stratification variables: trial site and active haematological malignancy for 90-day mortality. ^‡Baseline characteristics: age; active metastatic cancer; type of admission (medical, elective surgical, or acute surgical); Sequential Organ Failure Assessment score ranging from 0 to 24, with higher values indicating more severe organ failure. ^¶Life support was defined as any use of mechanical ventilation (invasive ventilation, noninvasive ventilation or non-intermittent continuous positive airway pressure), circulatory support (vasopressor or inotropic infusion), or renal replacement therapy.

	Lower oxygenation group	Higher oxygenation group	Relative risk (95% CI)	Risk difference (95% CI)	Odds ratio (95% CI)	P-value
Primary outcome∗
90-Day all-cause mortality, n/n-total (%)	122/277 (44.0)	132/285 (46.3)
Adjusted for stratification variables†			0.98 (0.82–1.17)	−2.59 (−10.70 to 5.51)		0.83
Adjusted for stratification variables† and baseline characteristics‡					0.92 (0.64–1.32)	0.65
Secondary outcomes
1-Yr all-cause mortality, n (%)	145/277 (52.3)	159/285 (55.8)
Adjusted for site			0.97 (0.83–1.13)	−3.21 (−11.35 to 4.93)		0.67
Median number of days alive without life support in 90 days (IQR)¶	78 (1–87)	70 (0–86)				0.24
Mechanical ventilation	79 (1–87)	70 (0–87)
Circulatory support	83 (3–88)	78 (3–88)
Renal replacement therapy	90 (7–90)	85 (7–90)
Median number of days alive out of hospital in 90 days (IQR)	45 (0–74)	36 (0–71)				0.60
Number of patients with one or more SAE in the ICU within 90 days, n/n-total (%)	110/277 (39.7)	111/285 (38.8)	1.03 (0.84–1.26)	0.89 (−7.16 to 8.93)		0.77
New shock	101 (36.5)	106 (37.1)
New myocardial infarction	3 (1.1)	1 (0.4)
New ischemic stroke	5 (1.8)	5 (1.8)
New intestinal ischemia	8 (2.9)	7 (2.5)